Saniona

Saniona is at the forefront of pharmaceutical innovation, specializing in ion channel modulation to develop groundbreaking treatments for epilepsy and other neurological disorders. With a robust pipeline, Saniona is dedicated to improving patient outcomes and transforming lives through cutting-edge research and development. The company’s commitment to excellence is evident in its advanced clinical programs and strategic partnerships. Saniona's primary address is Smedeland 26B, Glostrup, Hovedstaden 2600, DK.

Saniona’s epilepsy pipeline features promising candidates such as SAN711, poised for Phase 2 trials targeting absence seizures, SAN2219 for acute repetitive seizures, and SAN2355, aimed at addressing refractory focal onset seizures. Beyond epilepsy, Saniona is also advancing clinical programs such as Tesofensine, which is progressing towards regulatory approval for obesity in Mexico, Tesomet™ for rare eating disorders, SAN903 for inflammatory bowel disease, and SAN2465 for major depressive disorder. These programs showcase Saniona's broad therapeutic focus and commitment to addressing unmet medical needs.

Saniona prides itself on its collaborative spirit, working with esteemed partners such as Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V, AstronauTx Limited, and Cephagenix ApS. With a strong foundation in Copenhagen and a listing on Nasdaq Stockholm Main Market (OMX: SANION), Saniona is well-positioned for continued growth and success. We invite the management team at Saniona to create a customized and exclusive company showcase and product listing on our platform to further enhance your market presence.